RCT | In patients with rheumatoid arthritis, Tofacitinib is associated with increased risk of infections compared to TNF inhibitors.
1 Sep, 2022 | 11:50h | UTC
Commentary on Twitter
Check out our latest paper on infections in #rheumatoid #arthritis patients from the ORAL Surveillance trial:
▶️ tofacitinib lead to higher infection rates (serious and non-serious) vs TNFi
▶️ increased rates more pronounced in patients aged > 65? https://t.co/3pVrnzzFWD pic.twitter.com/Kf7p6D0jBD
— ARD & RMD Open (@ARD_BMJ) August 11, 2022